Tugrul T. Kararli, PhD, MBA; Kurt Sedo; and Josef Bossart, PhD; believe the pharmaceutical industry has been paying increasing attention to the potential of Fixed-Dose Combination products, and in a series of three articles, examine the past, present, and future of these products with the intent of understanding their whats and whys.
EXECUTIVE INTERVIEW – Hermes Pharma: User-Friendly Dosage Forms, a Win-Win Situation for Patients & Pharma
Drug Development Executive: Dr. Thomas Hein, Director, Sales & Business Development at Hermes Pharma, discusses how user-friendly dosage forms help put patients first, their advantages for patients and pharmaceutical companies, as well as the challenges associated with their development and production.
Drug Development Executive: Andreas Schütte, Member of the Management Board, Plastics & Devices Division, discusses his important role in Gerresheimer’s divisional restructuring process, and how he is convinced the new structure better reflects customer requirements.
PREFILLABLE SYRINGE TECHNOLOGY – BD Neopak – Delivering the Next Generation in Glass Prefillable Syringes
Justin M. Wright, PhD, and Herve Soukiassian highlight significant development and commercial manufacturing investments in glass PFS container technology for the biotech industry with three key areas of focus: reducing overall variability, reducing SbVPs, and increasing glass strength and durability performance.
Chris Hurlstone says device developers – whether human factors experts or industrial designers, mechanical engineers, or risk analysis teams – know engineering of the click is critical, yet this aspect of device design, like many others, is frequently not given the attention it deserves.
EXECUTIVE INTERVIEW – Battelle: Innovation in Drug Delivery Through Integrated Science & Engineering
Drug Development Executive: Amy Heintz, PhD, Senior Research Scientist at Battelle, speaks about the company’s relationship with customers and the importance of integrating device design, formulation, and human factors in the development of safe and efficient drug delivery solutions.
Pierre Carlotti, Vice-President of Marketing and Communication for Aptar Pharma Prescription Division, talks about the market for auto-injectors and some relevant market trends, and explains how his company went about designing and developing a novel auto-injector.
BIOAVAILABILITY ENHANCEMENT – Navigating a Broad Spectrum of Solubilization Technologies: Part III of III
Marshall Crew, PhD, President & CEO, Agere Pharmaceuticals, Inc., concludes his multiple-part series discussing today’s most challenging issues in solubility.
EXECUTIVE INTERVIEW – Catalent Applied Drug Delivery Institute: Helping to Get Better Drugs to Waiting Patients, Encouraging the Adoption of Advanced Delivery Technologies
Drug Development Executive: Kurt Nielsen, PhD, CTO & SVP, Innovation & Growth, and Founding Institute Board Member, discusses the Institute, its goals, structure, and activities.
Zach Marks, MS, RPh, believes efficiency of vaccine use will be critical as the world population continues to grow and vaccine prices continue to rise, and ID administration can help reduce dose cost while potentially improving immunogenicity in traditional and hard-to-treat populations.
EXCLUSIVE ONLINE CONTENT
TriSalus Life Sciences & Roger Williams Medical Center Announce Initiation of Phase 1 Clinical Trial for a Novel Delivery Technology
TriSalus Life Sciences recently announced the initiation of a new clinical trial assessing the safety and feasibility of an innovative new treatment that combines its…..
Alkahest, Inc. recently announced the initiation of a Phase 2b clinical trial of its orally administered small molecule CCR3 inhibitor, AKST4290. The company has dosed the first….
Credence MedSystems, an innovator in injectable drug delivery technology for the biopharmaceutical industry, has received the Pharmapack Award for its….
Aptar Pharma recently announced that its patented Unidose Liquid System is the device delivering a new nasal spray approved by the US FDA as a rescue treatment for….
Codexis, Inc. and Nestlé Health Science have signed an agreement to advance a lead candidate discovered through a Strategic Collaboration Agreement (SCA) into preclinical….